#USA #New York #Levi & Korsinsky #Securities Class Action #Pacira BioSciences

Levi & Korsinsky Launches Class Action on Behalf of Pacira BioSciences Investors

In a significant move for shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX), Levi & Korsinsky, LLP has filed a securities class action lawsuit. This legal action aims to recover losses suffered by investors during an alleged period of securities fraud from August 2, 2023, to August 8, 2024.

Case Overview

The class action follows troubling news concerning Pacira's patent integrity. On August 9, 2024, the company announced unfavorable legal results regarding its patent dispute with eVenus, revealing that the court deemed its U.S. Patent No. 11,033,495, linked to its main product Exparel, invalid. This patent accounts for about 80% of Pacira's revenue, creating a ripple effect of concern regarding the company’s financial health and future market competition.

As analysts dissected the implications of the patent ruling, fears grew that this would lead to greater competition from generic alternatives, not to mention potential increases in litigation costs. Consequently, Pacira's stock, which closed at $22.36 on August 8, plummeted nearly 47%, hitting a low of $11.70 on August 9, further alarming investors caught off-guard by the rapid decline.

What This Means for Investors

Investors affected by these developments now face a critical period. Those who incurred losses from their investments in Pacira are urged to act quickly. The deadline to seek appointment as lead plaintiff is March 14, 2025. However, participation in any recovery does not necessitate serving in this capacity, which provides some relief for investors wishing to recoup their losses.

The attorneys at Levi & Korsinsky emphasize that class members could potentially recover compensation without the need for upfront costs, making this a risk-averse option for shareholders wishing to pursue justice.

Why Choose Levi & Korsinsky?

With over 20 years of experience in securities litigation, Levi & Korsinsky boasts a robust track record, successfully securing hundreds of millions of dollars for aggrieved investors. The firm employs a team of over 70 professionals, specializing in navigating complex securities issues. Their reputation is fortified by consistently ranking among the top securities litigation firms in the United States according to ISS Securities Class Action Services.

Contact Information

For shareholders interested in joining the lawsuit or seeking more information, they can reach out to Joseph E. Levi, Esq. via email at [email protected] or call (212) 363-7500. Additional details are available on their website, where investors can also fill out a lawsuit submission form relevant to their losses.

In conclusion, investors of Pacira BioSciences facing significant financial setbacks due to these recent developments have a viable pathway to seek compensation. With the backing of an experienced legal team, they can navigate the complexities of this class action without incurring financial risk upfront.